Now live: Pro — the full 13F research suite for serious investorsSee pricing →
5AM Venture Management, LLC

Q4 2023 · 13F-HR

5AM Venture Management, LLCholdings as filed

Filed 2024-02-14 · accession 0001104659-24-023676

$377.0M
Reported value
25
Positions
2023-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
29337E102ELVNENLIVEN THERAPEUTICS INC$71.4M18.9%5,160,975CommonSOLE
29384C108TRDAENTRADA THERAPEUTICS INC$66.5M17.6%4,408,379CommonSOLE
N69605108PHVSPHARVARIS N V$22.4M5.93%797,600CommonSOLE
15117B202CLDXCELLDEX THERAPEUTICS INC NEW$19.7M5.23%497,270CommonSOLE
61559X104MLTXMOONLAKE IMMUNOTHERAPEUTICS$18.3M4.85%302,630CommonSOLE
G1110E107BHVNBIOHAVEN LTD$17.1M4.54%399,972CommonSOLE
254604101IRONDISC MEDICINE INC$17.0M4.51%294,221CommonSOLE
252828108DNTHDIANTHUS THERAPEUTICS INC$15.3M4.06%1,472,264CommonSOLE
N5749R1002GHMERUS N V$14.3M3.80%521,531CommonSOLE
929033108VOR BIOPHARMA INC$14.3M3.80%6,361,723CommonSOLE
92790C104VRDNVIRIDIAN THERAPEUTICS INC$12.8M3.39%586,595CommonSOLE
60468T105MRTXEURMIRATI THERAPEUTICS INC$11.3M3.00%192,500CommonSOLE
92686J106VKTXVIKING THERAPEUTICS INC$10.9M2.89%585,000CommonSOLE
75120L100RALLYBIO CORP$8.7M2.30%3,630,724CommonSOLE
90240B106TYRATYRA BIOSCIENCES INC$7.7M2.04%554,979CommonSOLE
032724106ANABANAPTYSBIO INC$7.7M2.03%357,733CommonSOLE
810648105SCPHSCPHARMACEUTICALS INC$7.5M2.00%1,200,647CommonSOLE
98943L107ZNTLZENTALIS PHARMACEUTICALS INC$7.4M1.97%490,000CommonSOLE
85209E109SPRUCE BIOSCIENCES INC$6.9M1.84%2,364,000CommonSOLE
05370A108RNAGBPAVIDITY BIOSCIENCES INC$6.0M1.60%665,555CommonSOLE
19240Q201COGTCOGENT BIOSCIENCES INC$4.6M1.23%790,440CommonSOLE
59045L106MERSANA THERAPEUTICS INC$3.0M0.80%1,305,000CommonSOLE
438083107FIXXEURHOMOLOGY MEDICINES INC$2.8M0.73%4,535,919CommonSOLE
G3855L106GHRSGH RESEARCH PLC$2.3M0.62%404,404CommonSOLE
171757107CIDARA THERAPEUTICS INC$900,8020.24%1,134,511CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.